Jason Tucker

Dr. Jason Tucker

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2016 in Drug Delivery
Verified
Journal Article
Open access
PDF file
MWMingxing Wang
Mingxing Wang
BWBo Wu
Bo Wu
JTJason Tucker
Jason Tucker
PLPeijuan Lu
Peijuan Lu
QLQilong Lu
Qilong Lu
A series of poly (ester amines) (PEAs) constructed from low molecular weight polyethyleneimine (LPEI, Mw: 0.8k, 1.2k Da) and Pluronic (different molecular weight (Mw) and hydrophilic-lipophilic-balance (HLB)) components were synthesized, and evaluated in vitro and in vivo as gene delivery carriers. Most PEA polymers were able to bind and condense plasmid DNA effectively into particles of approximately 150 nm in solution at the polymer/DNA ratio of 5 and above. Transfection efficiency of the PEA polymers depends on particle size of the polymer/DNA complex, molecular weight and HLB of the Pluronics and the size of PEI within PEA composition, as well as the cell type. Significant improvement in gene delivery efficacy was achieved with PEA01/04/05 composed of Pluronic size (Mw: 3000–5000 Da), and HLB (12–18) in CHO, C2C12 and HSkM cell lines; and the effective transfection was reflected with PEA 01/04/07 composed of Pluronics with size (2000–5000 Da) and HLB (12–23) in mdx mice. The best formulation for pDNA delivery was obtained with PEA 01 producing transgene expression efficiency 5, 19-folds of that of PEI 25k in vitro and in vivo, respectively. These results potent some of these PEA polymers as attractive vehicles for gene or oligonucleotide delivery.

7 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJason Tucker
Jason Tucker
RDRavi Doddapaneni
Ravi Doddapaneni
PLPei Juan Lu
Pei Juan Lu
QLQi L Lu
Qi L Lu
Breast cancer is heterogenous in development and cell population with prognoses being highly dependent on numerous factors from driving mutations, biomarker expression and variation in extracellular environment, all affecting response to therapies. Recently, much attention has been given to the role of metabolic alteration in cancers, expanding from the Warburg effect to highlight unique patterns in different cancer cell populations for improving diagnostic and therapeutic approaches. We recently reported on modulation of mannosylation of α-dystroglycan with the metabolite ribitol in breast cancer lines. Here we investigate the effects of pentose sugars ribitol, ribose, and xylitol media supplementation in breast cancer cells by metabolomics and differential gene expression profiling. This combined approach revealed distinctive patterns of alterations in metabolic pathways by ribitol, contrasted with the closely related pentose ribose and pentitol xylitol. Significantly, ribitol supplementation enhances utilization of glucose by glycolysis, whereas ribose improves oxidative phosphorylation and fatty acid synthesis. Ribitol supplementation also increased levels of reduced glutathione (associated with a decrease in oxidative phosphorylation, gluconeogenesis), where ribose supplementation elevated levels of oxidized glutathione (GSSG) indicating an increase in oxidative stress. Treatment with ribitol also enhanced nucleotide biosynthesis. The apparent TCA cycle dysregulation, with distinctive pattern in response to the individual pentitol and pentose, such as ribitol increasing succinate and fumarate while decreasing citrate, demonstrate the adaptive capability of cancer cells to nutritional environment. This metabolic reprogramming presents new avenues for developing targeted therapies to cancers with metabolites, especially in combination with other drug treatments.

1 July 2015 in The American Journal of Pathology
Verified
Journal Article
Closed access
HAHiroyuki Awano
Hiroyuki Awano
ABAnthony Blaeser
Anthony Blaeser
EKElizabeth Keramaris
Elizabeth Keramaris
LXLei Xu
Lei Xu
JTJason Tucker
Jason Tucker
QLQi L. Lu
Qi L. Lu

1 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BWBo Wu
Bo Wu
MDMorgan Drains
Morgan Drains
SSSapana N. Shah
Sapana N. Shah
PLPei Juan Lu
Pei Juan Lu
VLVictoria Leroy
Victoria Leroy
QLQi L Lu
Qi L Lu
Limb Girdle Muscular Dystrophy 2I (LGMDR9) is one of the most common LGMD characterized by defects in glycosylation of α-dystroglycan (matriglycan) resulting from mutations of Fukutin-related protein (FKRP). There is no effective therapy currently available. We recently demonstrated that ribitol supplement increases levels of matriglycan in cells in vitro and in FKRP-P448L (P448L) mutant mouse model through drinking water administration. To be clinically relevant, we have now conducted a dose-escalating efficacy study by gavage in P448L mutant mice. Six months of ribitol treatment daily significantly rescued functions of skeletal, respiratory, and cardiac muscles dose-dependently. This was associated with a dose dependent increase in matriglycan and improvement in muscle pathology with reductions in muscle degeneration, inflammatory infiltration and fibrosis. Importantly, ribitol significantly increased life span and muscle functions of the female animals receiving treatment from 10 months of age. The only observed side effect was gastrointestinal tract bloating with loose stool and this effect is also dose dependent. The results validate the mechanism that ribitol as a pre-substrate of glycosyltransferase is able to compensate for the decreased function of mutant FKRP with restoration of matriglycan expression and provide a guidance for future clinical trial design.

1 September 2015 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
MWMingxing Wang
Mingxing Wang
BWBo Wu
Bo Wu
JTJason Tucker
Jason Tucker
PLPeijuan Lu
Peijuan Lu
QLQilong Lu
Qilong Lu
In this study, we investigated a series of cationic polyelectrolytes (PEs) with different size and composition for their potential to improve delivery of an antisense phosphorodiamidate morpholino oligomer (PMO) both in vitro and in vivo. The results showed that the poly(diallyldimethylammonium chloride) (PDDAC) polymer series, especially PE-3 and PE-4, improves the delivery efficiency of PMO, comparable with Endoporter-mediated PMO delivery in vitro. The enhanced PMO delivery and targeting to dystrophin exon 23 was further observed in mdx mice, up to fourfold with the PE-4, compared with PMO alone. The cytotoxicity of the PEs was lower than that of Endoporter and polyethylenimine 25,000 Da in vitro, and was not clearly detected in muscle in vivo under the tested concentrations. Together, these results demonstrate that optimization of PE molecular size, composition, and distribution of cationic charge are key factors to achieve enhanced PMO exon-skipping efficiency. The increased efficiency and lower toxicity show this PDDAC series to be capable gene/antisense oligonucleotide delivery-enhancing agents for treating muscular dystrophy and other diseases.

26 May 2015 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
MWMingxing Wang
Mingxing Wang
BWBo Wu
Bo Wu
JTJason Tucker
Jason Tucker
PLPeijuan Lu
Peijuan Lu
LBLauren E. Bollinger
Lauren E. Bollinger
QLQilong Lu
Qilong Lu
A series of cationic amphiphlic copolymers (Z series) constructed from Tween 85 and low molecular weight (Mw) polyethyleneimine (LPEI) have been evaluated for the delivery of antisense 2′-O-methyl phosphorothioate RNA (2′-OMePS) in both cell culture and dystrophic mdx mice. All Z copolymers improved the 2′-OMePS-induced dystrophin expression both in vitro and in vivo compared with PEI 25k formulated or 2′-OMePS alone. The most effective polymers are in the order of Z9 > Z3 > Z7, Z1, Z2, Z6 > others by formulation at the dose of 20 μg mL−1 in myoblast cell culture. Significantly enhanced exon-skipping of 2′-OMePS with Z polymers in mdx mice was obtained in the order of Z7 > Z9, Z3 > Z8, Z6 > others. The highest efficiency of targeted exon-skipping with Z7 [T85–PEI 2k (1 : 1)] reached over 8 fold compared with 2′-OMePS alone in mdx mice. Further analyses of the structure and function indicate that the more hydrophobicity and lower PEI content of the polymer microstructure are, the greater are the delivery efficiency and exon-skipping. The unique hydrophobic interactions between the Z polymers and 2′-OMePS likely create more stable complexes in primarily hydrophilic environments both in vitro and in vivo. The overall results suggested that Tween 85 modified LPEIs provide a promising delivery approach for applications of 2′-OMePS oligonucleotides as therapeutic reagents.